Reports
Reports
Sale
North America is leading the global market owing to the increasing prevalence of diabetes. Various factors contribute to the growth of the market, such as early adoption of drugs, availability of advanced therapies, and the availability of combination drugs.
It is also estimated that the Asia Pacific region is expected to grow at the fastest rate during the forecast period due to the high prevalence of diabetes, obesity, and cardiac arrhythmia-related issues, and government support for healthcare awareness and research activities.
Diabetic Neuropathy Market Size
Diabetic Neuropathy Treatment Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetes Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Diabetes Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Diabetes Epidemiology (2016-2031)
5.3 Europe Diabetes Epidemiology (2016-2031)
5.4 Asia Pacific Diabetes Epidemiology (2016-2031)
5.5 Latin America Diabetes Epidemiology (2016-2031)
5.6 Middle East and Africa Diabetes Epidemiology (2016-2031)
6 Global Diabetic Neuropathy Market Overview
6.1 Global Diabetic Neuropathy Market Historical Value (2017-2023)
6.2 Global Diabetic Neuropathy Market Forecast Value (2024-2032)
7 Global Diabetic Neuropathy Market Landscape
7.1 Diabetic Neuropathy: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Diabetic Neuropathy: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment Methods
7.2.3 Analysis by Distribution Channels
7.2.4 Analysis by End User
8 Diabetic Neuropathy Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Diabetic Neuropathy Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Diabetic Neuropathy Market Segmentation
11.1 Global Diabetic Neuropathy Market by Type
11.1.1 Market Overview
11.1.2 Peripheral Neuropathy
11.1.3 Autonomic Neuropathy
11.1.4 Proximal Neuropathy
11.1.5 Focal Neuropathy
11.2 Global Diabetic Neuropathy Market by Treatment Methods
11.2.1 Market Overview
11.2.2 Antidepressants
11.2.3 Anti-seizure Medications
11.2.4 Anticonvulsants
11.2.5 Electric Nerve Stimulation
11.2.6 Topical Medications
11.2.7 Others
11.3 Global Diabetic Neuropathy Market by Distribution Channels
11.3.1 Market Overview
11.3.2 Hospital Pharmacy
11.3.3 Retail Pharmacy
11.3.4 Online Pharmacies
11.3.5 Others
11.4 Global Diabetic Neuropathy Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Research Institutes
11.4.4 Specialty Clinics
11.5 Global Diabetic Neuropathy Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Diabetic Neuropathy Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Diabetic Neuropathy Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Diabetic Neuropathy Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Diabetic Neuropathy Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Diabetic Neuropathy Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 NeuroMetrix, Inc
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Allergan PLC
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Pfizer, Inc
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Eli Lilly and Company
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Novartis AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Janssen Global Services, LLC
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Teva Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 LUMITOS AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 GSK plc
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Astellas Pharma Inc
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Glenmark Pharmaceuticals Ltd
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Diabetic Neuropathy - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
In 2023, the market attained a value of USD 4.90 billion in 2023, driven by the increasing prevalence of diabetic patients across the globe.
The market size is anticipated to grow at a CAGR of 6.99% during the forecast period of 2024-2032 to achieve a value of USD 8.50 billion by 2032.
The rising cases of diabetes and launch of new products are the major factors driving the growth of the market.
North America has been leading the global market due to early adoption of drugs, availability of advanced therapies, and the availability of combination drugs.
The high cost of the product and the availability of alternatives for diabetic neuropathy are hindering the market growth.
Diabetes causes nerve damage, which is known as diabetic neuropathy. Diabetes-related high blood glucose levels, also known as blood sugar, and high levels of fats in the blood, such as triglycerides, can damage nerves over time.
The signs and symptoms of peripheral neuropathy include numbness, prickling, or tingling in your feet or hands that can spread up into your legs and arms. Sharp, jabbing, throbbing, or burning discomfort Touch sensitivity to the extreme.
The types of the condition include peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy.
The treatment methods include antidepressants, anti-seizure medications, anticonvulsants, electric nerve stimulation, and topical medications, among others.
The distribution channels in the market include hospital pharmacy, retail pharmacy, and online pharmacies, among others.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.